A consortium of investors including Sequoia Capital, China Merchants Medical and Healthcare Industry Equity Fund, WuXi AppTec and Greenwoods Investment led a $188m funding round in Stemirna Therapeutics, a drugs and vaccines maker. Additional investors include OrbiMed Healthcare Fund Management, China-focused Advantech Capital, Guoxin Guotong, CMB International, Efund, Forebright, Tsing Song Capital, and CITIC Securities. Stemirna is planning to use the proceeds to accelerate clinical trials of Covid-19 vaccine candidates, set up good manufacturing practice facility, and for pipeline advancement.